These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

761 related articles for article (PubMed ID: 24794408)

  • 1. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy.
    Masuko K; Wakita D; Togashi Y; Kita T; Kitamura H; Nishimura T
    Immunol Lett; 2015 Jan; 163(1):102-12. PubMed ID: 25479286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.
    Widenmeyer M; Griesemann H; Stevanović S; Feyerabend S; Klein R; Attig S; Hennenlotter J; Wernet D; Kuprash DV; Sazykin AY; Pascolo S; Stenzl A; Gouttefangeas C; Rammensee HG
    Int J Cancer; 2012 Jul; 131(1):140-9. PubMed ID: 21858810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
    Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
    Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
    Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
    Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high-affinity T-helper epitope enhances peptide-pulsed dendritic cell-based vaccine.
    Li A; Xiong S; Lin Y; Liu R; Chu Y
    DNA Cell Biol; 2011 Nov; 30(11):883-92. PubMed ID: 21612399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
    Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
    J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
    Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
    Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
    Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
    Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.
    Tomimaru Y; Mishra S; Safran H; Charpentier KP; Martin W; De Groot AS; Gregory SH; Wands JR
    Vaccine; 2015 Mar; 33(10):1256-66. PubMed ID: 25629522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice.
    Kasamatsu J; Takahashi S; Azuma M; Matsumoto M; Morii-Sakai A; Imamura M; Teshima T; Takahashi A; Hirohashi Y; Torigoe T; Sato N; Seya T
    Immunobiology; 2015 Jan; 220(1):74-82. PubMed ID: 25257859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
    Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
    Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
    Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
    Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
    Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
    J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.